

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number  
**WO 2004/014361 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/33**,  
C07D 519/00, A61P 31/04 // (C07D 519/00, 513:00,  
471:00) (C07D 519/00, 498:00, 471:00)

Essex CM19 5AW (GB). **SHEPPARD, Robert, John**  
[GB/GB]; GlaxoSmithKline, New Frontiers Science Park  
South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(21) International Application Number:  
PCT/EP2003/008153

(74) Agent: **VALENTINE, Jill, Barbara**; GlaxoSmithKline,  
980 Great West Road, Brentford, Middlesex TW8 9GS  
(GB).

(22) International Filing Date: 23 July 2003 (23.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0217294.8 25 July 2002 (25.07.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **GLAXO  
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,  
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DAVIES, David**,  
Thomas [GB/GB]; GlaxoSmithKline, New Frontiers  
Science Park South, Third Avenue, Harlow, Essex CM19  
5AW (GB). **ELDER, John, Stephen** [GB/GB]; Glaxo  
SmithKline, New Frontiers Science Park South, Third  
Avenue, Harlow, Essex CM19 5AW (GB). **FORREST**,  
Andrew, Keith [GB/GB]; GlaxoSmithKline, New Fron-  
tiers Science Park South, Third Avenue, Harlow, Essex  
CM19 5AW (GB). **JARVEST, Richard, Lewis** [GB/GB];  
GlaxoSmithKline, New Frontiers Science Park South,  
Third Avenue, Harlow, Essex CM19 5AW (GB). **PEAR-**  
**SON, Neil, David** [GB/GB]; GlaxoSmithKline, New  
Frontiers Science Park South, Third Avenue, Harlow,

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 2004/014361 A1

(54) Title: AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY

(57) Abstract: Cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bac-  
terial infections in mammals, particularly man.

**DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF  
SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION  
AND PROCESS TO OBTAIN IT.**

**5 FIELD OF THE INVENTION**

Denatured carob flour and the process to obtain it described in this specification will be applied in industry to develop dietary fiber products rich in condensed tannins for human consumption.

10

**DESCRIPTION OF PRIOR ART**

There is considerable interest in developing dietary fiber products rich in polyphenol compounds owing to the known protective role of these substances against cardiovascular disease by reducing hypercholesterolemia and their effects on the efficacy of the intestinal translocation and the prevention of colonic cancer.

Hence, to cite some studies from the literature, polyphenolic compounds present in different concentrations in dietary fiber and in different food compounds have important antioxidant effects (Pulido R, Bravo L, Saura-Calixto F. *Antioxidant activity of dietary polyphenols as determined by a modified ferric reducing/antioxidant power assay*. J Agric Food Chem (2000) 48(8): 3396-402), that can be used to prevent and treat certain diseases including cancer (Pool-Zobel BL, Adlercreutz H, Glei M, Liegibel UM, Sittlington J., Rowland I, Wahala K, Rechkemmer G. *Isoflavonoids and lignans have different potentials to modulate oxidative genetic damage in human colon cells*). Carcinogenesis (2000) 21(6): 1247-52). Nevertheless, there is only a small amount of condensed tannins in the different dietary fibers and products enriched in these natural polyphenols cannot be used in the chronic treatment of degenerative diseases because at these levels they have a strong astringent and antinutritional effect.

30

On the other hand, pectins, gums and other similar products, majority components of soluble fibers, although substances produced by their colonic fermentation (e.g. butyrate) have been found to have potentially therapeutic applications, important benefits for the immune system (Perez R. Stevenson f. Jhonson J., Morgan M., Ericson K. Hubbard N.E. Morand L. Ruduch S., Kaztnelson S. *Sodium butyrate upregulates Kupffer cells PGE-2 production and modulates immune function*. J. Surg. Res. (1998) 78, 1-6; Lim B.O. Yamada K. Nonaka M. Kuramoto Y.,

Hung P., Sugano M. *Dietary fibres modulate indices of intestinal immune function in rats*. J. Nutr. (1997) 127, 663-7.) and in the prevention of colonic cancer in cell culture studies (Sowa Y, Sakai T. *Butyrate as a model for "gene-regulating chemoprevention and chemotherapy"* biofactors (2000); 12 (1-4): 283-7), in human trials the results are  
 5 not as clear, probably because they ferment rapidly in the proximal colon and little butyrate arrives at the distal colon, the most common site of neoplastic processes (Perrin P, Pierre F, Patry Y, Champ M, Berreur M, Pardal G, Bornet F, Meflah K, Menanteau J. *Only fibers promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats*. Gut. (2001) 48(1): 53-61). Nevertheless, mainly because  
 10 of economic interest in animal production, the delaying effect of tannins on bacterial fermentation in the digestive tract is currently well known. Therefore, in suitable quantities they can regulate and delay the production of butyrate in the final portions of the colon and rectum.

15 Carob pulp is also rich in cyclitol and pinitol, a product that is transformed into inositol in the organism, a molecule of great interest for cell metabolism control (Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharmacol (2000) 130 (8): 1944-48). The object of the present invention is, therefore, to eliminate from the carob pulp a large proportion of its sugars and soluble tannins, but maintaining a significant  
 20 pinitol contents and to modify its condensed tannins to maintain its beneficial effects (hypolipaeamic activity), regulators of intestinal function, antioxidants etc), eliminate its astringent and antinutritional effects and to be able to use in this way the product as a dietary product for human or animal use, as well as a component in pharmaceuticals.

## 25 DESCRIPTION OF THE INVENTION

The denatured carob flour with low soluble tannin and sugar contents, described here, has the following composition, depending on the variety of fruit used:

30	Sugars .....	usually 2-15%, typically 3-10%
	Cyclitols (pinitol).....	usually 0.2-1.5%; typically 0.3-1%
	Lignins .....	usually 2-10% ; typically 2-7%
	Celluloses.....	usually 10-30% ; typically 15-28%
	Hemicelluloses.....	usually 3-20% ; typically 3-9%
35	Pectins.....	usually 1-6%; typically 2-5%
	Condensed tannins.....	usually 25-55%; typically 30-48%
	Protein.....	usually 3-9%; typically 4-8%

Water contents less than .....usually below 8%; typically below 6%

All percentages given are weight percentages (wt.-%) if not stated otherwise.

5

This carob flour is characterized by having an active ingredient with at least 25%, usually 30%, typically 40% of condensed carob tannins denatured thermally with a weight ratio of soluble to insoluble polyphenols less than 0.05 (solubility determined with water at 37°C). Evaluation of the polyphenol contents has been carried out by first  
10 determining the soluble tannin contents in water at 37°C stirring for 15 minutes; these are determined spectrophotometrically in this water with the *Folin-Ciocalteu* reagent (Singleton V.L. Rossi J.A. *Colorimetry of total phenolics with phosphomolybdicphosphotungstic acid reagents*. Am. J. Enol. Vitic (1965). 16:144-158). The insoluble polyphenols of the residue are determined by treatment with HCl-  
15 butanol according to the method of Hagerman and coworkers (Hagerman A.E. Zhao Y. Jonson S. *Methods for determination of condensed and hydrolyzable tannins*. In F. Shahidi (Ed), Antinutrients and phytochemicals in foods (p. 209-222). ACS symposium Series 662. Washington, DC. American Chemical Society).

20 In this invention, carob pulp, rich in condensed tannins, formed by polymerization of flavan-3-ol and its gallic esters with a strong astringent effect, are treated with heat (between usually 130 and 200°C, typically 140 and 150°C) to result in a change of structure of the polyphenols with partial degradation and polymerization and to eliminate astringency and interference with absorption of nutrients in the diet but  
25 maintaining most of its positive effects. It can, therefore, be used for human diet and nutrition (as ordinary foods, enriched foods, dietary foods, foods for special medical purposes or dietary supplements), without antinutritional problems, while the effects of these condensed tannins as a sequesterant of cholesterol and bile salts, as antioxidants, laxatives and regulators of intestinal fermentation are maintained. Furthermore  
30 applications in animal feed and pet food or in human and animal pharmaceuticals are possible.

The process to obtain the previously described carob flour consists in a series of steps, as follows:

- 35 a. **Cleaning the whole fruit:** Cleaning includes e.g dry (e.g. mechanical separation of contaminants) or wet (e.g. wash out with water) cleaning steps. Dependent on the cleaning procedure this step may additionally include a drying step. This

could be done e.g. in an air flow.

- b. **Crushing the carob fruits:** this could be done, e.g. by passing the carob fruit through a mill, typically a hammer mill, to shred the pods to pieces smaller than 3 cm.
- 5 c. **Separation of carob seeds and kibbled carob pulp:** the seed can be separated using a sieve with a suitably sized mesh, depending on the conditions of the process, the agronomical variety and the water contents of the fruit. As an alternative suitable process air classification or other mechanical or physical technologies can be used.
- 10 d. **Toasting (modification of the structure of condensed tannins):** this process is important to change the nutritional properties of the condensed tannins. This can be reached by toasting of the carob kibbles at temperatures usually between 130-200°C, typically between 140-150°C for a certain time period depending on the water content of the pulp and the particle size. Usual time periods for this  
15 toasting process are 5-60 minutes, typically 10-20 minutes.
- e. **Extraction process:** the toasted carob pulp is extracted with water or any other suitable solvent to remove the sugars and water-soluble tannins. The ratio of extraction material to solvent is usually higher than 1:20 (by weight), typically 1:4 (by weight). The extraction can be made at different temperatures usually in  
20 the range of 5-80°C, typically between 20-55°C. Extraction can be done e.g. in an simple extraction tank (with or without stirrer) or in a continuously operating extractor (counter current flow extraction). Dependent on the other extraction parameters extraction time usually lies between 5 minutes to 24 hours, typically between 15 minutes and 2 hours.
- 25 f. **Separation:** Separation of the water soluble components from the water insoluble parts can be done by several techniques including decantation, filtration, or centrifugation.
- g. **Milling:** the water-insoluble residue is ground to a fine powder by milling techniques. Preferred equipment is a colloidal mill, but also other milling  
30 techniques can be considered (e.g. ball mills). Reached particle sizes are below 250 µm (90% of particles below 250 µm), usually below 150 µm (90% of particles below 150 µm) and typically below 100 µm (90% of particles below 100 µm).
- h. **Optionally repetition of steps e. (extraction) and f. (separation)** to further  
35 reduce the water soluble constituents in the obtained residue. Two further extraction steps are sufficient to reach sugar contents usually below 15 % and typically below 10% in the insoluble residue.

- i. **Separation:** After the last extraction step the obtained residue is pressed, filtered, decanted, or centrifuged to eliminate as much as possible of the water.
  - j. **Drying:** To reduce the water content usually below 8%, typically below 6%. This can be managed by several drying techniques including a drying oven, spray drying, vacuum drying, drying in an air or inert gas stream. Temperatures should usually not lie above 140°C, typically not above 60-65°C.
  - k. **Classification (sieving):** dependent on the application the obtained product can be sieved to obtain standardized particle size limits.
- 10       The whole production process, as described above in the steps a-k, or parts of it, can also be done in a continuous way.

15       The properties of this denatured carob flour: hypocholesterolemic, regulator of gastrointestinal dynamics, bile salt chelant and antioxidant on which we base its potential dietary and pharmacological applications for both human and animals, have been demonstrated in a number of animal trials carried out in the Department of Nutrition of the Universidad Complutense de Madrid, of which we summarize some relevant results.

20       First of all, in experimental animals the influence of this denatured carob flour (DCF) on ingestion, weight increase, growth, fecal volume, fecal polyphenol and butyrates was studied. To do this, a total of three batches of 10 growing rats were fed isocaloric synthetic diets modified to suit their nutritional requirements in which the only variable was the type of dietary fiber used: 2% apple pectin in all batches as butyrate source and 5% in batch 1 of microcrystalline cellulose (Avicel R), 5% in batch 2 of carob fiber (NCF = Natural Carob Fibre) and 5% in batch 3 of DCF. It was found that intake of DCF did not affect weight increase in animals or the dietary efficacy of the diets compared to cellulose and it can, therefore, be concluded that the treatment has managed to eliminate the antinutritive effect of its condensed tannins, while the carob fiber (NCF), slightly but significantly reduces both parameters. The DCF increases fecal volume and weight compared to cellulose and results in a similar fecal volume and weight, at the same doses, as NCF, but with fecal butyrate and polyphenol concentrations 30% and 10% higher, respectively, in rats fed with our invention than in those fed with diets containing carob fiber (NCF), hence, as repeatedly described by several authors, protection against the formation of mutagenic or carcinogenic compounds (electrophilic molecules) in animals that consume DCF is higher than that achieved with carob fibers (NCF).

To determine its effects on blood lipids, 30 young rats with experimental hypercholesterolemia were used (total cholesterol 235 mg/dl), 5 groups with 10 rats each were formed and the following fiber sources were added to their diets:

5

Batch 1-10% cellulose

Batch 2-10% carob fiber (NCF)

Batch 3-10 % carob flour (DCF)

10

After three weeks of treatment mean serum cholesterol levels were:

Batch 1: 285 mg/dl

Batch 2: 165 mg/dl

Batch 3-112 mg/dl

15

The conclusions of this study can be summarized as follows:

Taking into account that the cellulose used had no effect on cholesterolemia and that our invention (DCF) produced, significantly ( $p < 0.05$ ), the greatest reduction in serum cholesterol levels in animals, we can conclude that our invention has a more pronounced effect on cholesterolemia than natural carob fibers (NCF). This effect seems to be mediated by more sequestration of bile salts by DCF.

20

The percentages, temperatures and other additional factors associated with the product and with the process described can be variable provided that they are additional and secondary and do not alter the essence of the patent described here.

25

**CLAIMS:**

1. Denatured carob flour, characterized in that it comprises:  
2-15% Sugars, 0.2-1.5% Cyclitols (pinitol), 2-10% Lignins, 10-30% Celluloses, 3-  
5 20% Hemicelluloses, 1-6% Pectins, 25-55% Condensed tannins, 3-9% Protein and  
less than 8% Water.
2. Denatured carob flour according to claim 1, wherein the Sugar content is 3-10%.
- 10 3. Denatured carob flour according to claim 1 or 2, wherein the Cyclitols content is  
0.3-1%.
4. Denatured carob flour according to one of claims 1-3, wherein the Lignins content is  
2-7%.
- 15 5. Denatured carob flour according to one of claims 1-4, wherein the Celluloses  
content is 15-28%.
6. Denatured carob flour according to one of claims 1-5, wherein the Hemicelluloses  
20 content is 3-9%.
7. Denatured carob flour according to one of claims 1-6, wherein the Pectins content is  
2-5%.
- 25 8. Denatured carob flour according to one of claims 1-7, wherein the Condensed  
Tannins content is 30-48%.
9. Denatured carob flour according to one of claims 1-8, wherein the Protein content is  
4-8%.
- 30 10. Denatured carob flour according to one of claims 1-9, wherein the Water content is  
less than 6%.
11. Process to obtain a flour according to claim 1, comprising the following steps:  
35 a. Cleaning the whole fruit;  
b. Crushing the carob fruits;  
c. Separation of carob seeds and kibbled carob pulp;



- d. **Toasting** between 130-200°C
  - e. **Extraction process**;
  - f. **Separation**:
  - g. **Milling**: 90% of particles below 250 µm
  - 5 h. **Separation**:
  - i. **Drying**: below 8%,
  - j. **Classification (sieving)**:
12. Process according to claim 11, wherein in step b. the carob pod is shredded into  
10 pieces smaller than 3 cm.
13. Process according to claim 11 or 12, wherein the temperature is between 140-150°C
14. Process according to one of claims 11-13, wherein the time period for the toasting  
15 process is 5-60 minutes
15. Process according to claim 14, wherein the time period is 10-20 minutes.
16. Process according to one of claims 11-15, wherein in step e. the extraction is  
20 performed in the range of 5-80°C.
17. Process according to one of claims 11-16, wherein in step e. the ratio of pulp to  
water is 1:20 (wt./wt.).
- 25 18. Process according to one of claims 11-17, wherein in step e. the extraction is  
performed for 5 minutes to 24 hours.
19. Process according to one of claims 11-18, wherein in step g. 90% of particles are  
below 150 µm.  
30
20. Process according to one of claims 11-19, wherein between steps g. and h. steps e.  
and f. are at least once repeated.
21. Process according to one of claims 11-20, wherein in step i. the drying is performed  
35 at a temperature which does not exceed 140 °C.8%

22. Process according to one of claims 11-21, wherein the process is carried out continuously.

23. The use of the flour according to claim 1 in foods, dietary supplements, animal feed,  
5 pet food, human and animal medicine.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08636

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A23L1/0526 A23L1/308

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, FSTA

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 856 313 A (DIAZ CARLOS SANJUAN ET AL) 5 January 1999 (1999-01-05) the whole document	1-23
A	US 4 999 197 A (WUERSCH PIERRE) 12 March 1991 (1991-03-12) the whole document	1-23
A	US 5 330 755 A (THOMAS REMI) 19 July 1994 (1994-07-19) the whole document	1-23
A	US 5 624 500 A (SANJUAN DIAZ CARLOS) 29 April 1997 (1997-04-29) the whole document	1-23
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 December 2003

Date of mailing of the international search report

29/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Vernier, F

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/08636

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MARAKIS S: "CARBO BEAN IN FOOD AND FEED: CURRENT STATUS AND FUTURE POTENTIALS - A CRITICAL APPRAISAL" JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, ASSOCIATION OF FOOD SCIENTISTS AND TECHNOLOGISTS, US, vol. 33, no. 5, 1996, pages 365-383, XP009015221 ISSN: 0022-1155 the whole document</p> <p>-----</p>	1-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08636

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5856313 A	05-01-1999	ES 2060543 A1	16-11-1994
		AT 202676 T	15-07-2001
		DE 69427605 D1	09-08-2001
		DE 69427605 T2	29-05-2002
		DK 616780 T3	15-10-2001
		EP 0616780 A2	28-09-1994
		GR 3036791 T3	31-01-2002
		PT 616780 T	28-12-2001
		US 5609905 A	11-03-1997
US 4999197 A	12-03-1991	EP 0214317 A1	18-03-1987
		AT 36448 T	15-09-1988
		AU 586012 B2	29-06-1989
		AU 6093986 A	05-03-1987
		CA 1270440 A1	19-06-1990
		DE 3564370 D1	22-09-1988
		ES 2003342 A6	01-11-1988
		GR 862195 A1	31-12-1986
		IN 163759 A1	05-11-1988
		JP 2042719 C	09-04-1996
		JP 7080779 B	30-08-1995
		JP 62051622 A	06-03-1987
		MX 168213 B	12-05-1993
		OA 8385 A	29-02-1988
		PH 22386 A	12-08-1988
		PT 83276 A , B	01-09-1986
		US 5043160 A	27-08-1991
		ZA 8605889 A	25-03-1987
US 5330755 A	19-07-1994	EP 0525236 A1	03-02-1993
		AT 164765 T	15-04-1998
		BR 9202942 A	30-03-1993
		DE 69129229 D1	14-05-1998
		DE 69129229 T2	30-07-1998
		JP 3111115 B2	20-11-2000
		JP 5194249 A	03-08-1993
		MX 9204437 A1	01-01-1993
		OA 9796 A	15-04-1994
		PT 100745 A	30-09-1993
		RU 2072858 C1	10-02-1997
US 5624500 A	29-04-1997	ES 2060544 A1	16-11-1994
		AT 196931 T	15-10-2000
		DE 69426085 D1	16-11-2000
		DE 69426085 T2	10-05-2001
		DK 617133 T3	05-02-2001
		EP 0617133 A2	28-09-1994
		GR 3035113 T3	30-03-2001
		PT 617133 T	30-04-2001
		US 5451262 A	19-09-1995